Clinical Trials Logo

Advanced Breast Cancer clinical trials

View clinical trials related to Advanced Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04188548 Active, not recruiting - Breast Cancer Clinical Trials

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

EMBER
Start date: December 10, 2019
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

NCT ID: NCT03966898 Active, not recruiting - Clinical trials for Advanced Breast Cancer

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Start date: July 19, 2019
Phase: Phase 3
Study type: Interventional

This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.

NCT ID: NCT03927456 Active, not recruiting - Clinical trials for Advanced Breast Cancer

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Start date: June 13, 2019
Phase: Phase 3
Study type: Interventional

This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.

NCT ID: NCT03685331 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

NCT ID: NCT03538171 Active, not recruiting - Clinical trials for Advanced Breast Cancer

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Start date: May 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this randomized phase III trial is to evaluate the clinical benefit of combining entinostat with exemestane in Chinese patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer, who have disease progression on endocrine therapy. Additionally,the safety, tolerability, and PK profile of the treatment combination are evaluated.

NCT ID: NCT03282825 Active, not recruiting - Clinical trials for Advanced Breast Cancer

Clinical Study of Decitabine and Paclitaxel Combination Therapy

Start date: March 28, 2017
Phase: Phase 1
Study type: Interventional

Phase Ib clinical study of Decitabine and Paclitaxel combination therapy

NCT ID: NCT02499146 Active, not recruiting - Clinical trials for Advanced Breast Cancer

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Start date: September 11, 2015
Phase: Phase 1
Study type: Interventional

As part of the global clinical development program for Palbociclib, studies are planned in cancer patients in China. An assessment of Palbociclib pharmacokinetics in Chinese patients, as required by the Chinese Health Authorities, is therefore warranted. In addition, safety and efficacy will be also evaluated. The single and multiple 125 mg oral dose pharmacokinetics of Palbociclib will be characterized.

NCT ID: NCT00717951 Active, not recruiting - Clinical trials for Advanced Breast Cancer

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Start date: May 2008
Phase: Phase 2
Study type: Interventional

Docetaxol plus capecitabine regimen is the standard treatment for the anthracycline-pretreated patients with advanced breast cancer. Cisplatin is an important drug for advanced breast cancer and potential effective drug for triple negative breast cancer.The study primary objective:Assess ORR,TTP,TTF and 2 year PFS rate between docetaxol+capecitabine and docetaxol+cisplatin. The second objective:Assess the safety and QOL.

NCT ID: NCT00454805 Active, not recruiting - Clinical trials for Advanced Breast Cancer

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.